Stone Run Capital LLC held its position in shares of Merck & Company, Inc. (NYSE:MRK) during the first quarter, Holdings Channel reports. The institutional investor owned 5,939 shares of the company’s stock at the end of the first quarter. Stone Run Capital LLC’s holdings in Merck & were worth $377,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Merck & during the fourth quarter valued at $1,628,824,000. Dodge & Cox purchased a new position in shares of Merck & during the fourth quarter valued at $821,068,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Merck & during the fourth quarter valued at $252,822,000. Bank of Montreal Can increased its position in shares of Merck & by 49.7% in the first quarter. Bank of Montreal Can now owns 8,991,093 shares of the company’s stock valued at $571,295,000 after buying an additional 2,983,319 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Merck & by 70.4% in the first quarter. Canada Pension Plan Investment Board now owns 5,568,791 shares of the company’s stock valued at $353,841,000 after buying an additional 2,300,200 shares in the last quarter. 73.73% of the stock is owned by institutional investors.
Merck & Company, Inc. (NYSE MRK) traded down 0.11% during mid-day trading on Thursday, reaching $62.42. 1,596,178 shares of the company were exchanged. Merck & Company, Inc. has a 1-year low of $58.29 and a 1-year high of $66.80. The company has a market capitalization of $170.73 billion, a price-to-earnings ratio of 33.80 and a beta of 0.80. The company has a 50 day moving average of $63.56 and a 200-day moving average of $63.81.
Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The company had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. During the same quarter in the previous year, the business posted $0.93 EPS. The firm’s revenue was up .9% on a year-over-year basis. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 3.01%. The ex-dividend date is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.
TRADEMARK VIOLATION NOTICE: “Stone Run Capital LLC Has $377,000 Stake in Merck & Company, Inc. (MRK)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2797731/stone-run-capital-llc-has-377000-stake-in-merck-company-inc-mrk.html.
Several research analysts have commented on MRK shares. Zacks Investment Research raised shares of Merck & from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a report on Wednesday, May 10th. J P Morgan Chase & Co increased their price objective on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. BMO Capital Markets increased their price objective on shares of Merck & from $68.00 to $70.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price objective for the company in a report on Monday, May 15th. Finally, BidaskClub downgraded shares of Merck & from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $69.80.
In other Merck & news, Director C Robert Kidder sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $63.54, for a total transaction of $317,700.00. Following the completion of the transaction, the director now owns 14,317 shares in the company, valued at approximately $909,702.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.05% of the company’s stock.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.